BioRestorative Therapies, Inc.
BRTX
$2.74
-$0.06-2.24%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 357.90K | 359.70K | 383.40K | 605.20K | 391.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 357.90K | 359.70K | 383.40K | 605.20K | 391.00K |
| Cost of Revenue | 28.30K | 23.80K | 25.50K | 33.10K | 30.90K |
| Gross Profit | 329.60K | 335.90K | 357.90K | 572.10K | 360.10K |
| SG&A Expenses | 5.18M | 5.89M | 5.70M | 5.63M | 5.36M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.58M | 16.01M | 14.90M | 13.70M | 12.64M |
| Operating Income | -14.23M | -15.65M | -14.51M | -13.09M | -12.25M |
| Income Before Tax | -11.06M | -14.24M | -12.67M | -10.72M | -12.10M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.06 | -14.24 | -12.67 | -10.72 | -12.10 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.06M | -14.24M | -12.67M | -10.72M | -12.10M |
| EBIT | -14.23M | -15.65M | -14.51M | -13.09M | -12.25M |
| EBITDA | -14.01M | -15.44M | -14.30M | -12.89M | -12.06M |
| EPS Basic | -21.76 | -32.11 | -29.55 | -25.57 | -29.41 |
| Normalized Basic EPS | -13.60 | -20.07 | -15.84 | -13.35 | -15.75 |
| EPS Diluted | -21.76 | -32.11 | -29.55 | -25.57 | -29.41 |
| Normalized Diluted EPS | -13.60 | -20.07 | -15.84 | -13.35 | -15.75 |
| Average Basic Shares Outstanding | 2.27M | 1.80M | 1.72M | 1.67M | 1.64M |
| Average Diluted Shares Outstanding | 2.27M | 1.80M | 1.72M | 1.67M | 1.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |